You have free access to this content

Cancer

Cover image for Vol. 123 Issue 1

January 1, 2017

Volume 123, Issue 1

Pages 1–179

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
  2. CancerScope

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      First person: Margaret Spitz, MD, MPH (pages 9–10)

      Carrie Printz

      Version of Record online: 16 DEC 2016 | DOI: 10.1002/cncr.30464

    2. You have free access to this content
    3. You have free access to this content
  3. Commentary

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited (pages 12–16)

      Jay S. Cooper, Catherine Fortpied, Vincent Gregoire, Quynh-Thu Le, Thomas F. Pajak, Qiang (Ed) Zhang and Jacques Bernier

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30266

      • image
      • image

      A recent review in this journal in which the National Comprehensive Cancer Network's recommendations (based in part on results from the Radiation Therapy Oncology Group 9501 and European Organization for Research and Treatment of Cancer 22931 trials) were criticized warrants comment. To address many of the points and misinterpretations raised in that review, additional data are provided that convincingly support the use of concomitant chemotherapy and radiotherapy in patients who have good performance status and high-risk pathologic features after surgery for mucosal head and neck squamous cell carcinoma.

  4. Editorials

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      The known unknown (pages 17–19)

      Fadlo R. Khuri

      Version of Record online: 16 DEC 2016 | DOI: 10.1002/cncr.30487

      Cancer care and its application have differed for some time between the developed and the developing nations. These differences are likely to deepen with the onset of high-impact, high-cost molecular diagnostics, immunotherapy, and targeted therapy.

    2. You have full text access to this OnlineOpen article
      We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas (pages 20–24)

      Victor M. Villalobos, Brianna Hoffner and Anthony D. Elias

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30377

      Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well-defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90-7.

    3. You have free access to this content
      The Affordable Care Act, or Obamacare, 3 years later: A reality check (pages 25–28)

      Hagop M. Kantarjian

      Version of Record online: 11 OCT 2016 | DOI: 10.1002/cncr.30384

      Enacted 3 years ago, the Patient Protection and Affordable Care Act continues to be the subject of intense discussions and controversy. Herein, the progress in health care promulgated by implementation of the Patient Protection and Affordable Care Act is reviewed, persistent issues and unforeseen consequences discussed, and remedial solutions proposed.

  5. Review Article

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      Prostate cancer: Developing novel approaches to castration-sensitive disease (pages 29–42)

      Edoardo Francini and Mary-Ellen Taplin

      Version of Record online: 1 NOV 2016 | DOI: 10.1002/cncr.30329

      • image

      Multimodality approaches including chemotherapy and novel hormonal agents are frequently investigated in early-stage prostate cancer with the aim of maximizing the response efficacy and duration for patients with castration-sensitive disease. Immunotherapy and experimental molecules are also being actively explored in this setting.

  6. Original Articles

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer (pages 43–51)

      Christopher R. Friese, Yun Li, Irina Bondarenko, Timothy P. Hofer, Kevin C. Ward, Ann S. Hamilton, Dennis Deapen, Allison W. Kurian and Steven J. Katz

      Version of Record online: 24 OCT 2016 | DOI: 10.1002/cncr.30324

      • image
      • image
      • image
      • image

      In a population-based sample of women diagnosed with early-stage breast cancer, the majority of women, including a third of women with lymph node–positive disease, received 21-gene recurrence score testing. The test results correlated with guideline-recommended treatment in most cases, and patient satisfaction was high.

    2. Gastrointestinal Disease
      You have free access to this content
      Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis (pages 52–61)

      Zhaomin Xu, Supriya Gupta Mohile, Mohamedtaki Abdulaziz Tejani, Adan Z. Becerra, Christian P. Probst, Christopher T. Aquina, Bradley J. Hensley, Reza Arsalanizadeh, Katia Noyes, John R.T. Monson and Fergal J. Fleming

      Version of Record online: 25 AUG 2016 | DOI: 10.1002/cncr.30261

      • image
      • image
      • image
      • image
      • image

      The objective of the current study was to examine the rate of adjuvant chemotherapy and associated survival in patients with stage II/III rectal cancer. The current analysis reports a 22-fold difference in the rate of adjuvant chemotherapy administration across hospitals, and adjuvant chemotherapy appears to be independently associated with improved overall survival regardless of stage of disease, pathologic response, and patient factors.

    3. Head and Neck Disease
      You have free access to this content
      Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale development and validation (pages 62–70)

      Katherine A. Hutcheson, Martha P. Barrow, Denise A. Barringer, Jodi K. Knott, Heather Y. Lin, Randal S. Weber, Clifton D. Fuller, Stephen Y. Lai, Clare P. Alvarez, Janhavi Raut, Cathy L. Lazarus, Annette May, Joanne Patterson, Justin W. G. Roe, Heather M. Starmer and Jan S. Lewin

      Version of Record online: 26 AUG 2016 | DOI: 10.1002/cncr.30283

      • image
      • image
      • image
      • image

      With the development of the Dynamic Imaging Grade of Swallowing Toxicity, the modified barium swallow rating has been adapted to the National Cancer Institute's Common Terminology Criteria for Adverse Events framework of ordinal toxicity grading used in oncology trials. The Dynamic Imaging Grade of Swallowing Toxicity offers a psychometrically sound measure of dysphagia for head and neck cancer clinical trials and for investigations of toxicity profiles, dose responses, and predictive modeling.

    4. You have free access to this content
      Oral health and human papillomavirus-associated head and neck squamous cell carcinoma (pages 71–80)

      Angela L. Mazul, James M. Taylor, Kimon Divaris, Mark C. Weissler, Paul Brennan, Devasena Anantharaman, Behnoush Abedi-Ardekani, Andrew F. Olshan and Jose P. Zevallos

      Version of Record online: 29 AUG 2016 | DOI: 10.1002/cncr.30312

      Findings from this study suggest that poor oral health represents a common risk factor for both human papillomavirus (HPV)-positive and HPV-negative oropharyngeal cancers. Future research is required to elucidate interactions between poor oral health, tobacco use, and HPV in the development of oropharyngeal cancer.

    5. Hepatobiliary Disease
      You have free access to this content
      Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States (pages 81–89)

      Ju Dong Yang, Sean F. Altekruse, Mindie H. Nguyen, Gregory J. Gores and Lewis R. Roberts

      Version of Record online: 29 AUG 2016 | DOI: 10.1002/cncr.30246

      • image
      • image
      • image

      Country of birth appears to be independently associated with age at the time of diagnosis of hepatocellular carcinoma in the United States. Birth in Africa (except for North Africa) and Oceania is strongly associated with the very early onset of hepatocellular carcinoma.

    6. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor (pages 90–97)

      Scott M. Schuetze, Vanessa Bolejack, Edwin Choy, Kristen N. Ganjoo, Arthur P. Staddon, Warren A. Chow, Hussein A. Tawbi, Brian L. Samuels, Shreyaskumar R. Patel, Margaret von Mehren, Gina D'Amato, Kirsten M. Leu, David M. Loeb, Charles A. Forscher, Mohammed M. Milhem, Daniel A. Rushing, David R. Lucas, Rashmi Chugh, Denise K. Reinke and Laurence H. Baker

      Version of Record online: 3 OCT 2016 | DOI: 10.1002/cncr.30379

      • image
      • image

      Dasatinib demonstrates no significant antisarcoma activity in patients with epithelioid sarcoma or solitary fibrous tumor. Patients with alveolar soft part sarcoma have prolonged disease progression–free and overall survival, but this is not necessarily caused by dasatinib. A small minority of patients with chondrosarcoma or chordoma experience an objective tumor response or prolonged stabilization of disease, and this suggests that dasatinib treatment should be further evaluated for these sarcoma subtypes. See also pages 20-4.

    7. Discipline

      Disparities Research
      You have free access to this content
      Lay health educators increase colorectal cancer screening among Hmong Americans: A cluster randomized controlled trial (pages 98–106)

      Elisa K. Tong, Tung T. Nguyen, Penny Lo, Susan L. Stewart, Ginny L. Gildengorin, Janice Y. Tsoh, Angela M. Jo, Marjorie L. Kagawa-Singer, Angela U. Sy, Charlene Cuaresma, Hy T. Lam, Ching Wong, Mi T. Tran and Moon S. Chen Jr

      Version of Record online: 26 AUG 2016 | DOI: 10.1002/cncr.30265

      • image
      • image

      Asian American individuals have lower rates of colorectal cancer screening compared with non-Hispanic white individuals. In the current study, an educational intervention trial for Hmong Americans using lay health educators demonstrates increased colorectal cancer screening rates.

    8. You have free access to this content
      Genetic Ancestry using Mitochondrial DNA in patients with Triple-negative breast cancer (GAMiT study) (pages 107–113)

      Roshni Rao, Aeisha Rivers, Asal Rahimi, Rachel Wooldridge, Madhu Rao, Marilyn Leitch, David Euhus and Barbara B. Haley

      Version of Record online: 1 SEP 2016 | DOI: 10.1002/cncr.30267

      • image
      • image

      Genetic ancestry testing is an emerging medical field. Patients with triple-negative breast cancer tend to be younger and are more likely to be African American, making this an ideal disease for mitochondrial DNA exploration. The results of the current study demonstrate that mitochondrial DNA analysis in patients with triple-negative breast cancer reveals predominant patterns that may indicate an increased risk of developing aggressive disease.

    9. Epidemiology
      You have free access to this content
      Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods (pages 114–121)

      Tejal A. Patel, Mamta Puppala, Richard O. Ogunti, Joe E. Ensor, Tiancheng He, Jitesh B. Shewale, Donna P. Ankerst, Virginia G. Kaklamani, Angel A. Rodriguez, Stephen T. C. Wong and Jenny C. Chang

      Version of Record online: 29 AUG 2016 | DOI: 10.1002/cncr.30245

      • image
      • image

      Mammography research is inherently limited due to the time and expense required to manually extract data from unstructured free text mammogram reports. The authors have developed a natural language processing system that accurately extracts mammographic findings from free text reports. In the current study, they use this novel natural language processing system and statistical data mining to demonstrate the relationship between mammographic imaging characteristics and breast cancer subtype.

    10. You have free access to this content
      Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study (pages 122–130)

      Lori Muffly, Daphne Lichtensztajn, Parveen Shiraz, Renata Abrahão, Jennifer McNeer, Wendy Stock, Theresa Keegan and Scarlett Lin Gomez

      Version of Record online: 13 SEP 2016 | DOI: 10.1002/cncr.30322

      • image
      • image

      Despite abundant research and awareness related to the management of adolescents and young adults with acute lymphoblastic leukemia (ALL) over the past decade, wide variation exists in the approach to these patients, with only a minority treated following pediatric-inspired ALL protocols. Patients treated at higher volume adolescent and young adult ALL centers are more likely to receive pediatric ALL induction regimens.

    11. Outcomes Research
      You have free access to this content
      Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up (pages 131–137)

      Hannah Y. Wen, Melissa Krystel-Whittemore, Sujata Patil, Fresia Pareja, Zenica L. Bowser, Maura N. Dickler, Larry Norton, Monica Morrow, Clifford A. Hudis and Edi Brogi

      Version of Record online: 15 AUG 2016 | DOI: 10.1002/cncr.30271

      • image

      The current study evaluates the outcome of 1406 patients with early-stage, lymph node-negative, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer and an Oncotype Dx recurrence score (RS) <18, and notes a very low rate of distant recurrence at a median follow-up of 46 months (0.2% among patients with an RS of 0-10 and 0.6% in patients with an RS of 11-17). However, among the patients with an RS of 11 to 17, the absolute rate of distant metastasis among patients aged <40 years is 7.1%, versus 0.2% among patients aged ≥40 years.

    12. You have free access to this content
      Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort (pages 138–143)

      Jordan A. Holmes, Jeannette T. Bensen, James L. Mohler, Lixin Song, Merle H. Mishel and Ronald C. Chen

      Version of Record online: 13 SEP 2016 | DOI: 10.1002/cncr.30315

      There is a move toward quality indicators in prostate cancer, but to the authors' knowledge little is known regarding how quality care affects patient outcomes. The authors believe this study is the first to demonstrate an association between quality indicators and patient-reported outcomes.

    13. Pediatric Oncology
      You have free access to this content
      A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG (pages 144–154)

      Ricardo J. Flores, Aaron J. Kelly, Yiting Li, Manjula Nakka, Donald A. Barkauskas, Mark Krailo, Lisa L. Wang, Laszlo Perlaky, Ching C. Lau, M. John Hicks and Tsz-Kwong Man

      Version of Record online: 16 AUG 2016 | DOI: 10.1002/cncr.30272

      • image
      • image
      • image
      • image

      This study reports a novel model including the circulating concentrations of C-X-C motif chemokine ligand 10 (CXCL10) and Fms-related tyrosine kinase 3 ligand (FLT3LG) to prognosticate pediatric osteosarcoma patients at diagnosis. The model improves on the current prognostic factor at diagnosis, the presence of metastatic lesions, and may provide potential therapeutic targets in upcoming clinical trials for improving the survival of high-risk osteosarcoma patients.

    14. You have free access to this content
      Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging—A prospective trial (pages 155–160)

      Lars M. Wagner, Nathalie Kremer, Michael J. Gelfand, Susan E. Sharp, Brian K. Turpin, Rajaram Nagarajan, Gregory M. Tiao, Joseph G. Pressey, Julie Yin and Roshni Dasgupta

      Version of Record online: 26 AUG 2016 | DOI: 10.1002/cncr.30282

      • image

      Sentinel lymph node biopsy using lymphoscintigraphy and single-photon emission computed tomography/computed tomography for anatomic localization is a safe and effective method for identifying regional nodal metastases that may alter therapy. Positron emission tomography/computed tomography does not have sufficient sensitivity or specificity to eliminate the need for tissue sampling.

    15. You have free access to this content
      A prospective study of cerebral, frontal lobe, and temporal lobe volumes and neuropsychological performance in children with primary brain tumors treated with cranial radiation (pages 161–168)

      Harold Agbahiwe, Arif Rashid, Alena Horska, E. Mark Mahone, Doris Lin, Todd McNutt, Kenneth Cohen, Kristin Redmond, Moody Wharam and Stephanie Terezakis

      Version of Record online: 29 AUG 2016 | DOI: 10.1002/cncr.30313

      • image
      • image
      • image
      • image
      • image

      The radiation therapy dose and the cerebral volumes significantly correlate with vocabulary development in children treated with cranial radiation therapy. This prospective study supports clinical trials aimed at reducing cranial radiation therapy doses.

    16. Psychosocial Oncology
      You have free access to this content
      Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors (pages 169–176)

      Moriah J. Brier, Dianne L. Chambless, Robert Gross, Jinbo Chen and Jun J. Mao

      Version of Record online: 29 AUG 2016 | DOI: 10.1002/cncr.30318

      • image

      Aromatase inhibitors are a life-saving treatment for postmenopausal survivors of breast cancer, yet nonadherence is a prevalent problem. The results of this study demonstrate that patients' health beliefs, a potentially modifiable psychological factor, predict adherence to treatment with aromatase inhibitors over the course of 5 years.

  7. Correspondence

    1. Top of page
    2. Issue Information
    3. CancerScope
    4. Commentary
    5. Editorials
    6. Review Article
    7. Original Articles
    8. Correspondence
    1. You have free access to this content
      Nomograms need to be presented in full (pages 177–178)

      Gary S. Collins and Yannick Le Manach

      Version of Record online: 14 SEP 2016 | DOI: 10.1002/cncr.30347

    2. You have free access to this content
      Reply to Nomograms need to be presented in full (pages 178–179)

      Horace C.W. Choi, Wei Xu and Anne W.M. Lee

      Version of Record online: 14 SEP 2016 | DOI: 10.1002/cncr.30345

      • image

SEARCH

SEARCH BY CITATION